Friends of Cancer Research announced the publication of a commentary on the significance of pragmatic clinical trials in ESMO Real World Data and Digital Oncology.
Findings by Friends of Cancer Research were published recently in JCO Clinical Cancer Informatics in a paper titled “Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in mNSCLC patients treated with chemotherapy.”
A study led by researchers at NYU Langone Health and its Perlmutter Cancer Center has highlighted the role of DNA methylation in the increased risk of several cancers, including breast cancer, among rescuers and survivors of the attack on the World Trade Center on Sept. 11, 2001, in New York City.
People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to an analysis by Johns Hopkins Kimmel Cancer Center investigators.
Mayo Clinic study has found that 8 million to 10 million Americans over age 40 have an overabundance of cloned white blood cells, or lymphocytes, that hamper their immune systems. Although many who have this condition—called monoclonal B-cell lymphocytosis—do not experience any symptoms, a recent study shows they may have an elevated risk for several health complications, including melanoma.
ImmunityBio Inc. announced positive results from its QUILT 3.055 trial demonstrating long-term extended survival of 14 months to as much as five years for patients with advanced non-small cell lung cancer being treated with checkpoint inhibitors.
MAIA Biotechnology Inc. announced results showing a favorable interim survival benefit from its lead clinical candidate THIO, a telomere-targeting treatment for patients with advanced non-small cell lung cancer.
Research published in Communications Biology demonstrates the potential of Aqtual’s proprietary platform that evaluates gene regulation, epigenetics, and transcriptomics by analyzing previously unexplored cfDNA fragments found in blood, opening the door to novel clinical applications in almost every major disease area.
Johnson & Johnson announced results from the open-label phase II SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related reactions with intravenous Rybrevant (amivantamab-vmjw) in patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations.
A defensive mechanism responsible for normal remodeling of breast tissue during the menstrual cycle is a potential driver of breast cancer development, according to research by the Cancer Grand Challenges research team PRECISION.
